The Committee for the Protection of Human Subjects


COVID-19 Update: March 18, 2020

As announced on March 17 by Dean Madden, Dartmouth College Vice Provost for Research and Institutional Official for Human Subjects Research, in his message to faculty:

"Effective Monday March 23, as IO, I am placing an institutional hold on in-person interactions with human subjects beyond those interactions already required for non-research purposes, such as clinical care. Data analysis, survey work, and remote interviews may continue. Any exceptions will require approval from your Associate Dean (A&S), or Dean (Geisel, Tuck and Thayer), followed by CPHS review and approval. CPHS will review modifications that permit study continuation without additional in-person contact. Please continue to monitor the CPHS website for updates."

CPHS has determined that immediate changes to avoid in-person interactions with human subjects during the COVID-19 emergency meet the regulatory allowance that "change is necessary to eliminate an apparent immediate hazard" and therefore these changes do not require prior CPHS approval. Please plan to report these changes to the CPHS in a timely manner.

We will update the CPHS website with FAQ and updates as more information becomes available. 

Thank you,

Dartmouth College CPHS

Dartmouth College website COVID-19: Coronavirus information


The Committee for the Protection of Human Subjects (CPHS) is the Institutional Review Board (IRB) at Dartmouth College - a federally mandated committee with the charge of overseeing institutional research projects involving human participants. The CPHS serves as the IRB for Dartmouth College. 

The mission of the CPHS is to protect the rights and welfare of research participants.

The CPHS relies on the ethical principles identified in the Belmont Report in its review of research projects. These principles are respect for persons, beneficience and and its corollary non-maleficence, and justice.

The CPHS also adheres to applicable federal regulations for human subject protection. These regulations include 45 C.F.R. 46 and, when applicable, 38 C.F.R. 16, and 21 C.F.R. Parts 50 and 56. The CPHS recognizes and applies when appropriate the guidance of the International Committee on Harmonization (ICH), and Good Clinical Practices (GCP) as acknowledged by the Food and Drug Administration.

All submissions to CPHS must be completed via RAPPORT. RAPPORT is a web-based integrated research administration system that will manage submissions and correspondence with CPHS. Access RAPPORT at the link below.



Consideration for determining the IRB of record for a multi-site study.

If you are the PI of a project involving multiple sites, please contact the CPHS office to discuss a plan for IRB review prior to your submission for review. Please include the following information: the title, a brief description of the study, the number of sites and a brief description of the activities at each site.